Philis-Tsimikas A, Asong M, Franek E et al (2023) Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial
Jun 1 2023 Afaghi et al., Caspian J Intern Med, doi:10.22088/cjim.14.3.553 N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study 29% lower mortality (p=0.42) , 41% lower ventilation (p=0.16) , 20% lower ICU admission (p=0.36) , and 14% shorter hospitalization (p=0.002)
Key players include Novo Nordisk, Eli Lilly, and Pfizer
The injectable version is also approved for the treatment of the liver disease Metabolic-dysfunction-associated steatohepatitis (MASH)
[PubMed]^2 Richie, J.P
Research indicates that Semaglutide exerts its effects through both peripheral and central mechanisms: Central Nervous System (CNS) Signaling: Semaglutide crosses the blood-brain barrier, interacting with GLP-1 receptors in the hypothalamus (specifically the arcuate nucleus) and the hindbrain
